Chapter 129 All the heroes in the world are in the tent!

It can be said that he was in an extremely comfortable and pleasant state at this time, so it was naturally not easy to recruit him.

This situation will continue until next year, 2016, as the Broad Institute sees no prospect of CRISPR/Cas9 gene editing technology becoming profitable in the short term.

They gradually reduced the funding for the project, which eventually led to Zhang Feng no longer being able to maintain the glory of publishing several major papers a month. Only then did they have a chance to recruit Zhang Feng.

But that is a matter of the future. At least in 2015, Zhang Feng is still in a high position, and it is not easy to poach him now.

Of course, although it is impossible to poach people, there is no problem in purchasing some patent licenses from the Broad Institute or even buying out the technical patent licenses.

After all, if CRISPR/Cas9 gene editing technology wants to be truly profitable, it will have to be in 2024.

In fact, it was not until 2024 in the previous life that the world's first gene-edited medical product was approved for marketing by the United States.

Therefore, according to past history, this CRISPR/Cas9 gene editing technology is destined to continue to lose money during this period and will not be able to make a profit.

In this case, as long as the money Lin Feng pays out satisfies them and allows them to recover some of their losses, they will naturally be able to obtain relevant technical patent authorization or even a technical patent buyout authorization!
……

Time flies quickly, and in the blink of an eye, more than ten days have passed, and it is March 2015, 3.

On this day, the news released by Starway Genomics and the Broad Institute caused a sensation in the domestic and international technology circles.

On this day, Starway Genomics announced that it had spent $2.3 million to purchase a series of CRISPR/Cas9 gene editing technology patent buyout licenses held by the Broad Institute.

Suddenly, CRISPR/Cas9 gene editing technology once again made a sensation in the media, drawing their attention to this aspect.

But the big fuss caused by Xingtu Gene Company is not limited to this.

Within two days, Starway Genetics Company officially reached a technology patent licensing buyout agreement with the Max Planck Institute.

Starway Genetics spent $1.5 million to purchase a series of CRISPR/Cas9 gene editing technology patent buyout licenses held by the Max Planck Institute.

In addition, it was announced that Dr. Charpentier and Dr. Doudna, the inventors of CRISPR/Cas9 gene editing technology, have officially joined Star Path Genetics.

Behind this announcement, Xingtu Gene Company also made a big fuss about the treatment of the two female doctors, which made people jealous for a while.

After all, after joining Starway Genetics, not only will you have a triple annual salary, but each person will also have $2 million in exclusive scientific research funds each year. This is really enviable!

When this news came out, countless scientific researchers around the world were so jealous that their teeth were etched with envy.

After all, this is a huge amount of scientific research funding of 2 million US dollars per person per year. How many well-known large companies in their country can't earn more than 2 million US dollars a year.

But the control over so much scientific research funding belongs to one person...

All of a sudden, Dr. Charpentier and Dr. Doudna became truly famous all over the world.

Although people often express envy, jealousy and hatred when talking about them, and wish they could replace them, it has to be said that the effect of spending a fortune on horse bones is still very good.

When Xingtu Gene Company spread the treatment of the two doctors everywhere through the news and public opinion channels of domestic and foreign Internet giants.

Countless experts and talents in the field of genetic research and development at home and abroad have submitted their resumes to Xingtu Gene, hoping to join the company.

After all, Xingtu Gene is really too rich and willing to spend money.

Faced with such a boss who is stupid and rich, they naturally want to join Xingtu Gene Company.

Lin Feng was naturally overjoyed at this, and then he selected the best candidates for admission.

In less than half a month, Xingtu Gene Company successfully recruited more than a dozen experts in the field of genetic research.

Each of them is either a big shot now or will be a big shot in a few years.

For example, in 2016 in the previous life, the CRISPR-Cas9 plant gene editing technology was successfully developed.

Dr. Gao Caixia has achieved precise and low-cost editing of plant genes without leaving any foreign DNA.

This CRISPR-Cas9 plant gene editing technology is another milestone breakthrough in plant biotechnology after the establishment of genetically modified plant technology.

After she and the small team she brought with her joined the company, they naturally continued to do their old job, developing plant gene editing technology.

Of course, in addition to this, Lin Feng also recruited Professor He Jian, who created the world's first gene-edited baby in his previous life. Although this guy created gene-edited babies in his previous life, he was eventually sentenced to several years in prison for this, and he can be regarded as a true mad scientist.

But one has to admit that this guy is still very talented. Lin Feng just needs to limit his performance and prevent him from gene-editing babies like he did in his previous life.

After all, you can't always be thinking about the issue of future babies being immune to AIDS. You should also be thinking about how to solve the problem of people being infected with AIDS now.

Under such circumstances, he should use his wisdom to develop gene-edited medical products that can help people today overcome AIDS.

This can also prevent him from taking the wrong path again and being sentenced to three years in prison again, so it is better to let him follow the path of his previous life than to let him go.

Lin Feng still decided to give him a chance and let him walk the right path, and indirectly prevent the incident of gene-edited babies from happening again, avoiding a heavy blow to the field of gene editing.

Of course, in addition to these two Chinese experts in the field of gene editing, there are actually many other scientific research experts in the field of gene editing.

For example, Professor Ji Weizhi, who created the world's first CRISPR gene-edited monkey last year.

For example, Professor Yang Hui invented the GOTI off-target detection technology in 2019, which increased the accuracy of off-target detection by one million times.

For example, the two core scientific researchers who previously followed Zhang Feng were Dr. Le and Dr. Wang Yi.

After seeing the amazing treatment offered by Xingtu Gene, they also had their own little ideas. Compared to working under Zhang Feng, it would be better to lead a scientific research project independently.

So they finally joined Star Path Genetics, and are now in charge of a gene editing research project at the company.

As for foreign countries, there are also many experts and talents in the field of genetics. As long as the scientific research projects they propose are not too unfavorable, Lin Feng will approve them all.

It can be said that in just half a month, Xingtu Gene Company directly recruited more than a dozen experts in the field of CRISPR-Cas9 gene editing technology, and there are as many as 200 senior researchers assisting them.

From now on, CRISPR-Cas9 gene editing technology will have three major camps.

They are the former Max Planck Institute camp, the Broad Institute camp and the Star Path Genomics Company camp.

Although the Max Planck Institute lost Dr. Charpentier and Dr. Doudna, Europe still has talents.

Just three days after Dr. Charpentier and Dr. Doudna left, they found a suitable successor to directly take over the research projects of Dr. Charpentier and Dr. Doudna.

So now CRISPR-Cas9 gene editing technology has formed three major research and development camps, in addition to other large and small research and development institutions.

After all, CRISPR-Cas9 gene editing technology is now open source, so as long as your product has no commercial use, you can research it as you like.

So now there are too many companies around the world that are simultaneously developing CRISPR-Cas9 gene editing technology.

However, those companies can be ignored because their R&D progress will never catch up with Starway Genetics.

Because Xingtu Gene Company has used facts to tell people how terrifying the speed of scientific research is when the three are combined: artificial intelligence Jarvis + unmanned automatic laboratories + top genetic R&D talents.

……

On May 2015, 5, one and a half months had passed since Xingtu Gene launched a series of major moves.

American Empire, Broad Institute.

The Broad Institute was founded in 2004 and is backed by Harvard University and the Massachusetts Institute of Technology. It has been in a state of rapid development since its establishment.

Ten years later, the Broad Institute already had 400 full-time researchers, and the number of researchers from its collaborating Harvard University and Massachusetts Institute of Technology reached over 3000.

Under such circumstances, Church, the director of the Broad Institute, who should have been smiling all the time, frowned deeply as he looked at the Nature magazine in front of him.

Because the important paper in front of him came from Xingtu Gene Company.

This paper tells the story of how Star Path Genetics analyzed 3000 genes using the artificial intelligence Jarvis.

Thirty-six viral genes were discovered "lurking" in the human genome, 36 of which were newly confirmed DNA fragments from viruses that had never been seen before.

This means that millions of years ago, these viruses invaded human ancestors and integrated their genetic information into the human genome, starting a long latent journey.

(End of this chapter)